Shingles Vaccine Market Analysis

Shingles Vaccine Market Analysis

Based on product, the market is classified into Shingrix, Zostavax, and SKYZoster. The Shingrix segment generated the highest revenue of USD 4.2 billion in 2024.
 

• Shingrix’s recombinant formulation provides robust and durable protection against shingles, which is especially beneficial for the aging population, who are at greater risk for the disease and its complications. Its effectiveness remains strong over time, reducing the need for additional doses, unlike older live-attenuated vaccines. This long-lasting immunity makes Shingrix a cost-effective solution, increasing its adoption rates globally.
   
• Leading health organizations, such as the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), strongly recommend Shingrix for adults over the age of 50, as well as for certain immune-compromised groups. These endorsements have driven higher vaccination rates, particularly in North America and Europe, where shingles prevention is widely prioritized.
   
• Additionally, since Shingrix does not contain a live virus, it is considered safe for individuals with weakened immune systems, who previously had limited options for shingles prevention. The safety and efficacy of Shingrix in these populations have expanded its recommended use, broadening the scope of shingles vaccination and further strengthening Shingrix’s market position.
   

Based on vaccine type, the shingles vaccine market is segmented into recombinant vaccine and live attenuated vaccine. The recombinant vaccine segment dominated the market in 2024 and is anticipated to reach USD 11.3 billion by the end of the forecast period.
 

• Recombinant shingles vaccines demonstrate over 90% efficacy, offering robust and long-lasting protection against shingles, even among high-risk populations. This strong and sustained immunity is essential for the aging demographic, as they are most susceptible to shingles and its severe complications. The longer duration of immunity provided by recombinant vaccines, compared to live attenuated vaccines, makes them a preferred choice, reducing the need for additional doses and follow-up.
   
• Additionally, pharmaceutical companies producing recombinant vaccines, such as GlaxoSmithKline with Shingrix, have expanded production and distribution networks globally, making recombinant vaccines widely accessible. Strategic partnerships with healthcare providers, pharmacies, and public health organizations have helped bring recombinant vaccines to a broad patient base, ensuring consistent availability and reinforcing their market dominance.
   

North America shingles vaccine market accounted for USD 2.7 billion in market revenue in 2024 and is anticipated to grow at a CAGR of 9.6% between the 2025 to 2034.
 

• North America holds a significant share of the market, driven by high awareness of shingles prevention, favorable healthcare policies, and strong support from public health organizations. In the U.S., the Centers for Disease Control and Prevention (CDC) actively recommends shingles vaccination for adults aged 50 and older, leading to the widespread adoption of vaccines such as Shingrix.
   
• Additionally, healthcare insurance coverage for shingles vaccination under Medicare and other private insurance plans increases accessibility, making it easier for older adults to get vaccinated. With an aging population and proactive public health initiatives, North America continues to be a leading region in the market.
   

France shingles vaccine market is projected to grow remarkably in the coming years.
 

• French health authorities recognize the risks posed by shingles and its complications, particularly postherpetic neuralgia, which disproportionately affects older adults.
   
• The national healthcare system’s support for vaccination programs, including subsidies and insurance coverage, makes the vaccine accessible to a large portion of the target demographic.
   
• This strong support from the healthcare system, along with an aging population, contributes to France’s significant share in the European market.
   

Japan holds a dominant position in the Asia Pacific shingles vaccine market.
 

• With one of the highest proportions of elderly individuals globally, Japan faces a substantial public health challenge in managing shingles and its complications. To address this, healthcare authorities in Japan are increasingly promoting shingles vaccination for seniors.
   
• The Japanese government has implemented initiatives to increase vaccine awareness and expand coverage, making shingles vaccination more accessible through healthcare providers and public health programs. These efforts, combined with a proactive approach to elderly healthcare, contribute to Japan's substantial share in the market.